Patient and treatment characteristics
| Variable . | Result . |
|---|---|
| Median patient age, y (range) | 33 (18-66) |
| Male sex, n (%) | 26 (53) |
| Stage, n (%) | |
| IIA | 15 (31) |
| IIB | 5 (10) |
| III | 18 (37) |
| IV | 11 (22) |
| Bulky mediastinal mass, n (%)* | 15 (31) |
| GHSG classification, n (%) | |
| Early favorable | 2 (4) |
| Early unfavorable | 15 (31) |
| Advanced | 32 (65) |
| IPS in advanced disease, n | |
| 0 | 2 |
| 1 | 7 |
| 2 | 10 |
| 3 | 9 |
| 4 | 1 |
| 5 | 3 |
| > 5 | 0 |
| Histologic type, n | |
| Nodular sclerosis | 37 |
| Mixed cellularity | 4 |
| Lymphocyte rich | 1 |
| Lymphocyte deplete | 2 |
| Classic, NOS | 5 |
| HRS cell CD20 status, n (%)† | |
| Positive | 4 (8) |
| Negative | 44 (90) |
| Unknown | 1 (2) |
| Tumor EBV status, n (%)‡ | |
| Positive | 8 (16) |
| Negative | 40 (82) |
| Unknown | 1 (2) |
| Number of ABVD cycles (%)§ | |
| 6 | 48 (98) |
| 2 | 1 (2) |
| Documented G-CSF use, n (%)§ | 8 (16) |
| Omission of first-dose rituximab, n (%)‖ | 17 (35) |
| Consolidative radiation therapy, n (%)§¶ | 4 (8) |
| Variable . | Result . |
|---|---|
| Median patient age, y (range) | 33 (18-66) |
| Male sex, n (%) | 26 (53) |
| Stage, n (%) | |
| IIA | 15 (31) |
| IIB | 5 (10) |
| III | 18 (37) |
| IV | 11 (22) |
| Bulky mediastinal mass, n (%)* | 15 (31) |
| GHSG classification, n (%) | |
| Early favorable | 2 (4) |
| Early unfavorable | 15 (31) |
| Advanced | 32 (65) |
| IPS in advanced disease, n | |
| 0 | 2 |
| 1 | 7 |
| 2 | 10 |
| 3 | 9 |
| 4 | 1 |
| 5 | 3 |
| > 5 | 0 |
| Histologic type, n | |
| Nodular sclerosis | 37 |
| Mixed cellularity | 4 |
| Lymphocyte rich | 1 |
| Lymphocyte deplete | 2 |
| Classic, NOS | 5 |
| HRS cell CD20 status, n (%)† | |
| Positive | 4 (8) |
| Negative | 44 (90) |
| Unknown | 1 (2) |
| Tumor EBV status, n (%)‡ | |
| Positive | 8 (16) |
| Negative | 40 (82) |
| Unknown | 1 (2) |
| Number of ABVD cycles (%)§ | |
| 6 | 48 (98) |
| 2 | 1 (2) |
| Documented G-CSF use, n (%)§ | 8 (16) |
| Omission of first-dose rituximab, n (%)‖ | 17 (35) |
| Consolidative radiation therapy, n (%)§¶ | 4 (8) |
GHSG indicates German Hodgkin Study Group; IPS, International Prognostic Score; NOS, not otherwise specified; and G-CSF, granulocyte-colony stimulating factor.
Ratio ≥ 1/3 or > 10 cm. Either criterion for bulky mediastinal disease was considered a risk factor for GHSG risk classification.
Classified as CD20+ if at least a subset of HRS cells demonstrated membrane positivity by routine immunohistochemistry.
Based on either in situ hybridization for EBV-encoded RNA or latent membrane protein 1 immunohistochemistry.
ABVD dose reductions and delays, cycles beyond 6, G-CSF, and radiation therapy were optional.
Permitted in urgent cases.
None given for early favorable disease.